Point estimation following two‐stage adaptive threshold enrichment clinical trials
暂无分享,去创建一个
Nigel Stallard | Susan Todd | Peter K Kimani | Lindsay A Renfro | S. Todd | N. Stallard | P. Kimani | L. Renfro
[1] John V Heymach,et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. , 2012, The Lancet. Oncology.
[2] Werner Brannath,et al. Shrinkage estimation in two‐stage adaptive designs with midtrial treatment selection , 2013, Statistics in medicine.
[3] Jack Bowden,et al. Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules , 2016, Statistics in medicine.
[4] R. Kolamunnage-Dona,et al. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review , 2016, PloS one.
[5] M. Posch,et al. Optimizing Trial Designs for Targeted Therapies , 2016, PloS one.
[6] K. Yu,et al. A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations , 2010, Clinical trials.
[7] Jack Bowden,et al. Accounting for selection and correlation in the analysis of two-stage genome-wide association studies , 2016, Biostatistics.
[8] Nigel Stallard,et al. Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials , 2018 .
[9] John Whitehead,et al. On the bias of maximum likelihood estimation following a sequential test , 1986 .
[10] N. Simon,et al. Adaptive enrichment designs for clinical trials. , 2013, Biostatistics.
[11] Jack Bowden,et al. Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.
[12] Nigel Stallard,et al. Estimation after subpopulation selection in adaptive seamless trials , 2015, Statistics in medicine.
[13] R. Simon,et al. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. , 2007, Journal of the National Cancer Institute.
[14] Xiaoyun Li,et al. Estimation of treatment effect in two‐stage confirmatory oncology trials of personalized medicines , 2017, Statistics in medicine.
[15] Noah Simon,et al. Using Bayesian modeling in frequentist adaptive enrichment designs , 2018, Biostatistics.
[16] M. Rietschel,et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression , 2009, British Journal of Psychiatry.
[17] James Wason,et al. An adaptive design for updating the threshold value of a continuous biomarker , 2016, Statistics in medicine.
[18] M. Kieser,et al. Point estimation in adaptive enrichment designs , 2017, Statistics in medicine.
[19] Lindsay A. Renfro,et al. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer , 2017, Clinical Cancer Research.
[20] Thomas Jaki,et al. Estimation in multi‐arm two‐stage trials with treatment selection and time‐to‐event endpoint , 2017, Statistics in medicine.
[21] J Jack Lee,et al. Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[23] Jenny Y. Zhang,et al. Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study. , 2017, Contemporary clinical trials.
[24] C. Morris. Parametric Empirical Bayes Inference: Theory and Applications , 1983 .
[25] Nigel Stallard,et al. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility , 2013, Statistics in medicine.
[26] K. Ballman,et al. Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Daniel J Sargent,et al. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. , 2014, Chinese clinical oncology.
[28] Nigel Stallard,et al. Point estimates and confidence regions for sequential trials involving selection , 2005 .
[29] Jiunn T. Hwang. EMPIRICAL BAYES ESTIMATION FOR THE MEANS OF THE SELECTED POPULATIONS , 2016 .
[30] Harold B. Sackrowitz,et al. Two stage conditionally unbiased estimators of the selected mean , 1989 .
[31] D. Kupfer,et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. , 2004, Controlled clinical trials.
[32] W. Brannath,et al. Selection and bias—Two hostile brothers , 2009, Statistics in medicine.
[33] K. Tansey,et al. Biomarkers predicting treatment outcome in depression: what is clinically significant? , 2012, Pharmacogenomics.
[34] N Stallard,et al. Adaptive designs for clinical trials assessing biomarker-guided treatment strategies , 2014, British Journal of Cancer.